Pliant Therapeutics (PLRX) investor relations material

Executive summary

• Focused on integrin-based therapeutics, with lead candidate PLN-101095 in Phase 1b for solid tumors; bexotegrast program discontinued in 2025 due to safety concerns and unfavorable risk-benefit profile.

• Dosed first participant in FORTIFY, a Phase 1b trial of PLN-101095, ahead of schedule in April 2026.

• Presented updated Phase 1 data at AACR 2026, showing anti-tumor activity, deepening responses in checkpoint inhibitor-refractory solid tumors, and favorable safety.

• PLN-101095 highlighted as a novel immunotherapy approach at AACR's 2026 Highlights Plenary Session.

• Net loss for Q1 2026 was $20.0 million, a significant improvement from $56.2 million in Q1 2025, reflecting restructuring and pipeline reprioritization.

Financial highlights

• Q1 2026 research and development expenses decreased to $13.6 million from $43.4 million in Q1 2025, mainly due to discontinuation of bexotegrast and workforce reduction.

• General and administrative expenses fell to $8.2 million from $15.5 million year-over-year, reflecting lower headcount.

• Net loss per share improved to $(0.32) from $(0.92) year-over-year.

• Cash, cash equivalents, and short-term investments totaled $172.4 million as of March 31, 2026, expected to fund operations into the second half of 2028.

• No interest expense in Q1 2026 after full repayment of long-term debt in October 2025.

Outlook and guidance

• Interim data from the FORTIFY Phase 1b trial expected in 2027.

• Research and development expenses expected to remain consistent in the near term, increasing as the Phase 1b trial progresses.

• Cash runway projected into the second half of 2028, but additional capital will be needed for later-stage development.